NCT04937972View on ClinicalTrials.gov

SHR-1701 Combined With Fluzoparib in Lung Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

71

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

December 1, 2024

Study Completion Date

June 1, 2025

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

SHR-1701 Combined With Fluazopalil

SHR-1701 +fluzoparib

Trial Locations (1)

410013

RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors

lead

Hunan Province Tumor Hospital

OTHER